PROCEPT BioRobotics (PRCT) stock surged over 28% on Monday after the company exceeded third-quarter earnings expectations, showcasing strong revenue growth driven by increased system sales and robust utilization of its Aquablation technology. Analysts remain optimistic about the company’s future prospects, citing continued market penetration, improving profitability, and potential advancements in prostate cancer treatment.
PROCEPT BioRobotics (PRCT) stock surged over 28% on Monday after the company exceeded third-quarter earnings expectations, showcasing strong revenue growth driven by increased system sales and robust utilization of its Aquablation technology. Analysts remain optimistic about the company’s future prospects, citing continued market penetration, improving profitability, and potential advancements in prostate cancer treatment.
The Dow Jones Industrial Average climbed over 200 points on Monday, driven by strong gains in the healthcare and technology sectors. PROCEPT BioRobotics, Monte Rosa Therapeutics, and EyePoint Pharmaceuticals were among the top performers, fueled by positive financial results, licensing deals, and promising clinical trial data. Other notable movers include Revance Therapeutics, ImmunityBio, and Trump Media & Technology Group, while the Bitcoin surge boosted MicroStrategy and MARA Holdings.
On CNBC’s ‘Mad Money Lightning Round,’ Jim Cramer shared his insights on Target, Zoetis, PROCEPT BioRobotics, and Consolidated Edison. He praised Target’s strong second-quarter performance and Zoetis’s impressive financial results. While he highlighted the growth potential of PROCEPT BioRobotics, he recommended investors consider Intuitive Surgical (ISRG) instead for robotics investments. Cramer also expressed his continued confidence in Consolidated Edison, citing its consistent performance and attractive dividend yield.
